Physician profile
Gregory Parker
NPI 1972544625
$1,285.03
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $262 · 2021: $33.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $176.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $82.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $73.42 | 2019-2020 | |
| Pfizer INC. | $72.47 | 2019-2021 | |
| Exelixis INC. | $70.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.14 | 2019-2020 | |
| Tesaro, INC. | $66.72 | 2019 | |
| Astellas Pharma US INC | $50.14 | 2019-2020 | |
| Lilly USA, LLC | $47.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.31 | 2019 | |
| Emd Serono, INC. | $42.80 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $42.01 | 2019-2020 | |
| Abbvie INC. | $39.97 | 2019-2021 | |
| Daiichi Sankyo INC. | $37.67 | 2019 | |
| Taiho Oncology, INC. | $36.97 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.68 | 2019 | |
| Array Biopharma INC | $33.64 | 2019 | |
| Genzyme Corporation | $33.31 | 2019 | |
| Genentech USA, INC. | $33.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.16 | 2019-2020 | |
| Allergan, INC. | $24.79 | 2020 | |
| Novocure INC. | $24.31 | 2019 | |
| Karyopharm Therapeutics INC. | $24.08 | 2020 | |
| Verastem, INC. | $23.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.84 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.66 | 2019 | |
| Seagen INC. | $13.98 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.